Zanubrutinib plus salvage chemotherapy in patients with refractory/relapsed diffuse large B-cell lymphoma non-candidate for autologous stem cell transplantation: A retrospective study.

ABSTRACT: Salvage chemotherapy followed by autologous stem cell transplantation (auto-SCT) is effective for relapsed or refractory DLBCL (R/R DLBCL), but many patients are ineligible due to age, comorbidities, tolerance, economy and other factors. Zanubrutinib, a selective Bruton's tyrosine kinase inhibitor, has modest antitumor activity in R/R DLBCL. This study aimed to evaluate the efficacy and safety of zanubrutinib plus salvage chemotherapy in transplant-ineligible patients with R/R non-GCB DLBCL. We retrospectively reviewed patients with R/R non-GCB DLBCL treated with zanubrutinib combined with BR (bendamustine + rituximab; ZBR) or R2 (lenalidomide + rituximab; ZR2) between January 2019 and July 2023. A total of 49 patients were enrolled with a median age of 60 years. The best objective respons

SUBMITTER: He S 

PROVIDER: S-EPMC12619796 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature